Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo — Wegovy (semaglutide) is licensed and prescribed as a once-weekly injection only. Taking it twice a week is not how the medicine works, and doing so would significantly increase the risk of side effects without adding any clinical benefit. The dosing schedule is fixed by the medicine's licence and your prescriber sets it accordingly. If you're wondering whether injecting more often means faster results, the short answer is: it doesn't, and the pharmacology explains why. Wegovy's mechanism depends on semaglutide building up steadily in the body over days — that curve is calibrated to a weekly interval. Wegovy is a prescription-only medicine, so how and when you take it is determined by a clinical assessment and the guidance in your Patient Information Leaflet, not personal preference.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It's a reasonable thought. You're a few weeks in, the results feel slow, and the pen is right there in the fridge. A question our prescribers hear most weeks is some version of this: "Can I take it more often to get things moving faster?" The honest answer is no, and it's worth understanding why rather than just accepting the rule.
Semaglutide has a biological half-life of roughly seven days. That means it stays active in your body for around a week after each injection, gradually declining before the next dose tops it back up. The once-weekly interval is not an arbitrary choice, it's matched to that pharmacokinetic curve so that the drug maintains a steady, therapeutic level. Inject again on day three or four and you're not adding more effect; you're stacking one active dose on top of another. The broader question of semaglutide frequency applies equally here: the biology doesn't change based on urgency.
What does happen with doubled dosing is that side effects climb sharply. Nausea, vomiting, diarrhoea and stomach cramps are already the most commonly reported effects during the early titration phase; amplifying the plasma concentration makes all of those considerably more likely and more severe. There is no evidence that twice-weekly dosing improves weight outcomes. The clinical trial programme that led to Wegovy's UK licence studied the once-weekly schedule throughout, and that is the basis on which the medicine is approved. The NHS medicines page for semaglutide is clear that the injection is given once a week on the same day each week.
Wegovy treatment starts at 0.25 mg once weekly. The dose steps up roughly every four weeks through 0.5 mg, 1.0 mg and 1.7 mg, arriving at the 2.4 mg maintenance dose. The MHRA also approved a 7.2 mg maintenance dose in January 2026, available via a dedicated single-dose pen from April 2026. Each step is spaced out deliberately: moving too fast through the schedule is itself a source of GI side effects, which is why titration timing is something your prescriber controls.
The titration period can feel frustrating if you're expecting immediate change. But the graduated approach is why most people tolerate the medicine well by the time they reach a therapeutic maintenance dose. Trying to compress the schedule by injecting more often effectively recreates the problem the titration was designed to avoid. If your current dose feels insufficient, the right move is a conversation with your prescriber about whether a scheduled dose increase is appropriate, not adding an extra injection between doses.
If you're weighing up whether Wegovy is the right fit for you at all, including whether your BMI and any weight-related conditions meet the licensed criteria, the BMI thresholds for Wegovy cover that in detail. And if you're already on treatment and have questions about your specific schedule, our FAQs cover a range of practical queries, or you can reach the team directly through our contact page.
Real life doesn't always match a seven-day calendar. The practical guidance here is that if you've injected a dose earlier than planned, the answer is not to skip the next one to compensate and not to take a third dose to "get back on track". Adjusting your injection day is something your prescriber or the Patient Information Leaflet can walk you through clearly. The general principle, consistent with NHS guidance, is that if a dose was taken late or missed, you follow the leaflet's specific instructions rather than improvising the schedule.
If you're wondering whether taking a short break from Wegovy is appropriate (for surgery, illness, or another reason) that's a separate but related question worth reading. Equally, the question of injecting every other week comes up when people are trying to manage side effects or stretch supply; the clinical answer there is similarly grounded in how semaglutide behaves in the body. For those thinking about fortnightly dosing, the same pharmacokinetic reasoning applies.
None of these timing questions should be resolved alone. Wegovy requires a valid prescription, and every aspect of how it's taken (including any schedule adjustment) sits within the prescriber relationship. If you haven't yet started treatment and want to understand whether you're eligible and what the process involves, this overview of who can take Wegovy is a useful starting point, or you can explore all available weight-loss treatment options to find the right fit. The NHS England guidance on weight-management injections also covers dosing principles and the importance of clinical oversight throughout treatment.
If you're ready to speak with a prescriber about Wegovy, you can start your free consultation with our team.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.